Format

Send to

Choose Destination
See comment in PubMed Commons below
Regen Med. 2012 Jul;7(4):595-603. doi: 10.2217/rme.12.36.

US FDA outreach to the regenerative medicine community: challenges and opportunities.

Author information

1
California Institute for Regenerative Medicine, San Francisco, CA 94107, USA. kwhittlesey@cirm.ca.gov

Abstract

Advances in the field of regenerative medicine have yielded novel approaches to developing treatments for currently unmet medical needs. The regenerative medicine field is diverse, spanning many research and clinical disciplines; no single society or organization fully represents regenerative medicine. The US FDA maintains an active dialog with a variety of stakeholders to keep abreast of the latest available science, to anticipate regulatory challenges posed by the latest scientific developments and to educate stakeholders about regulatory expectations for product development. The diversity of stakeholders in this field makes this dialog challenging. This article provides an overview of some of the FDA's current outreach activities in this area. The FDA welcomes opportunities to enhance its interactions with the regenerative medicine community.

PMID:
22817631
DOI:
10.2217/rme.12.36
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center